Pill form of semaglutide may be a suitable option for adults with overweight or obesity, trial suggests

A Novo Nordisk designed trial reports that their 25 mg oral semaglutide taken once daily produced greater mean weight reduction than placebo over 64 weeks in adults with overweight or obesity.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup